News
15h
MoneyWeek on MSNCash in on the biotech boom with three promising European picksAilsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
U.S. senator wants to know how the FDA will enforce drug ad regulations after letting go numerous workers from the office ...
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up ...
ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing ...
Concord Biotech share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.
East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...
Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...
A biotech company has announced plans to acquire 23andMe after the genetic testing company filed for Chapter 11 bankruptcy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results